Skip to main content
See More

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drug

Leukemia volume 15, pages 1633–1640 (2001)Cite this article

Abstract

Although cyst(e)ine is nutritionally a non-essential amino acid, lymphoid cells cannot synthesize it, rendering their growth dependent on uptake of cyst(e)ine from their micro-environment. Accordingly, we previously suggested that the xc − plasma membrane cystine transporter provided a target for lymphoid cancer therapy. Its inhibition could lead to cyst(e)ine deficiency in lymphoma cells via reduction of both their cystine uptake and cysteine supply by somatic cells. In this study, using rat Nb2 lymphoma cultures, drugs were screened for growth arrest based on xc − inhibition. Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the xc − transporter. It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of xc −-mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid. Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures. In rats (n = 13), sulfasalazine (i.p.) markedly inhibited growth of well-developed, rapidly growing rat Nb2 lymphoma transplants without apparent side-effects. Reduced, macrophage-mediated supply of cysteine was probably involved. In five rats, 90–100% tumor growth suppression, relative to controls, was obtained. The xc − cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Poplack DG, Kun LE, Magrath IT, Pizzo PA . Leukemias and lymphomas of childhood In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology 4th edn JB Lippincott: Philadelphia 1993 pp 1792–1818

    Google Scholar 

  2. Gout PW, Horsman DE, Fox K, de Jong G, Ma S, Bruchovsky N . The rat Nb2 lymphoma: a novel model for tumor progression Anticancer Res 1994 14: 2485–2492

    CAS  PubMed  Google Scholar 

  3. Heppner GH, Miller FR . The cellular basis of tumor progression Int Rev Cytol 1998 177: 1–56

    CAS  PubMed  Google Scholar 

  4. Iglehart JD, York RM, Modest AP, Lazarus H, Livingston DM . Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin J Biol Chem 1977 252: 7184–7191

    Article  CAS  PubMed  Google Scholar 

  5. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR . Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells Leukemia 1997 11: 1329–1337

    Article  CAS  PubMed  Google Scholar 

  6. Gmünder H, Eck H-P, Dröge W . Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones Eur J Biochem 1991 201: 113–117

    Article  PubMed  Google Scholar 

  7. Broome JD, Jeng MW . Promotion of replication in lymphoid cells by specific thiols and disulfides in vitro J Exp Med 1973 138: 574–592

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ishii T, Hishinuma I, Bannai S, Sugita Y . Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol J Cell Physiol 1981 107: 283–293

    Article  CAS  PubMed  Google Scholar 

  9. Bannai S . Exchange of cystine and glutamate across plasma membrane of human fibroblasts J Biol Chem 1986 261: 2256–2263

    Article  CAS  PubMed  Google Scholar 

  10. Watanabe H, Bannai S . Induction of cystine transport activity in mouse peritoneal macrophages J Exp Med 1987 165: 628–640

    Article  CAS  PubMed  Google Scholar 

  11. Gmünder H, Eck H-P, Benninghoff B, Roth S, Dröge W . Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine Cell Immunol 1990 129: 32–46

    Article  PubMed  Google Scholar 

  12. Gout PW, Buckley AR, Simms CR, Bruchovsky, N . Novel lymphoma growth-inhibitory activity of the immunosuppressant, sulfasalazine. Proc 11th Int Congress Endocrinology, Sydney, Australia, October 29–November 2, 2000, p 313, No. P873 (Abstr.)

  13. Kluin-Nelemans HC, Limpens J, Meerabux J, Beverstock GC, Jansen JH, de Jong D, Kluin PM . A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21) Leukemia 1991 5: 221–224

    CAS  PubMed  Google Scholar 

  14. Krumenacker JS, Buckley DJ, Leff MA, McCormack JT, de Jong G, Gout PW, Reed JC, Miyashita T, Magnuson NS, Buckley AR . Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2 and bax expression Endocrine 1998 9: 163–170

    Article  CAS  PubMed  Google Scholar 

  15. Tomayko MM, Reynolds CP . Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother Pharmacol 1989 24: 148–154

    Article  CAS  PubMed  Google Scholar 

  16. Bannai S, Kasuga H . Anti-inflammatory drug inhibition of transport of cystine and glutamate in cultured human fibroblasts Biochem Pharmacol 1985 34: 1852–1854

    Article  CAS  PubMed  Google Scholar 

  17. Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J . Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays Can J Physiol Pharmacol 1997 75: 1088–1095

    Article  CAS  PubMed  Google Scholar 

  18. Ding XZ, Tong WG, Adrian TE . Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells Anticancer Res 2000 20: 2625–2631

    CAS  PubMed  Google Scholar 

  19. Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C . Indomethacin serum concentrations in man Ann Rheum Dis 1976 35: 333–338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kurowski M, Dunky A . Transsynovial kinetics of piroxicam in patients with rheumatoid arthritis Eur J Clin Pharmacol 1988 34: 401–406

    Article  CAS  PubMed  Google Scholar 

  21. Slattery JT, Levy G . Effect of ibuprofen on protein binding of warfarin in human serum J Pharm Sci 1977 66: 1060

    Article  CAS  PubMed  Google Scholar 

  22. Insel PA . Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout In: Hardman JG, Goodman Gilman A, Limbird LE (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th edn McGraw-Hill: New York 1996 pp 617–657

    Google Scholar 

  23. Ishii T, Bannai S, Sugita Y . Mechanism of growth stimulation of L1210 cells by 2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine J Biol Chem 1981 256: 12387–12392

    Article  CAS  PubMed  Google Scholar 

  24. Kopp E, Ghosh S . Inhibition of NF-kappa B by sodium salicylate and aspirin Science 1994 265: 956–959

    Article  CAS  PubMed  Google Scholar 

  25. Wahl C, Liptay S, Adler G, Schmid RM . Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B J Clin Invest 1998 101: 1163–1174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hoult JR . Pharmacological and biochemical actions of sulphasalazine Drugs 1986 32: (Suppl. 1) 18–26

    Article  CAS  PubMed  Google Scholar 

  27. Bach MK, Brashler JR, Johnson MA . Inhibition by sulfasalazine of LTC synthetase and of rat liver glutathione S-transferases Biochem Pharmacol 1985 34: 2695–2704

    Article  CAS  PubMed  Google Scholar 

  28. Guastavino E, Litwin NH, Heffes Nahmod L, Licastro R . Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment Acta Gastroenterol Latinoam 1988 18: 107–113

    CAS  PubMed  Google Scholar 

  29. Rahav G, Zylber-Katz E, Rachmilewitz D, Levy M . Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases Isr J Med Sci 1990 26: 31–34

    CAS  PubMed  Google Scholar 

  30. Almer S, Norlander B, Strom M, Osterwald H . Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission Scand J Gastroenterol 1991 26: 327–335

    Article  CAS  PubMed  Google Scholar 

  31. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RGB, Rudman D . Plasma cysteine, cystine, and glutathione in cirrhosis Gastroenterology 1984 87: 770–776

    Article  CAS  PubMed  Google Scholar 

  32. Sato H, Tamba M, Ishii T, Bannai S . Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins J Biol Chem 1999 274: 11455–11458

    Article  CAS  PubMed  Google Scholar 

  33. Iwata S, Hori T, Sato N, Hirota K, Sasada T, Mitsui A, Hirakawa T, Yodoi J . Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion J Immunol 1997 158: 3108–3117

    CAS  PubMed  Google Scholar 

  34. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS . NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis Mol Cell Biol 1999 19: 5923–5929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Keating MJ, Holmes R, Lerner S, Ho DH . L-Asparaginase and PEG asparaginase – past, present and future Leuk Lymphoma 1993 10: 153–157

    Article  PubMed  Google Scholar 

  36. Uren JR, Lazarus H . L-Cyst(e)ine requirements of malignant cells and progress toward depletion therapy Cancer Treat Rep 1979 63: 1073–1079

    CAS  PubMed  Google Scholar 

  37. Wada K, Kamisaki Y, Kitano M, Nakamoto K, Itoh T . Protective effect of cystathionine on acute gastric mucosal injury induced by ischemia-reperfusion in rats Eur J Pharmacol 1995 294: 377–382

    Article  CAS  PubMed  Google Scholar 

  38. Stabler SP, Lindenbaum J, Savage DG, Allen RH . Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency Blood 1993 81: 3404–3413

    Article  CAS  PubMed  Google Scholar 

  39. Kato S, Negishi K, Mawatari K, Kuo CH . A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion Neuroscience 1992 48: 903–914

    Article  CAS  PubMed  Google Scholar 

  40. Aoshiba K, Yasui S, Nishimura K, Nagai A . Thiol depletion induces apoptosis in cultured lung fibroblasts Am J Respir Cell Mol Biol 1999 21: 54–64

    Article  CAS  PubMed  Google Scholar 

  41. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ . Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion J Neurosci 1998 18: 6241–6253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Dr CT Beer and Dr MC Robertson (BC Cancer Agency, Canada) are thanked for helpful discussions, and DJ Buckley (Cincinnati Medical Center, USA) for preparing the northern blots. Dr S Bannai (University of Tsukuba, Ibaraki, Japan) is thanked for providing the 4F2hc and xCT cDNA probes, and the Department of Advanced Therapeutics of the BC Cancer Agency for supplying DoHH2 cells. This study was supported by the BC Cancer Foundation, with core support from the BC Cancer Agency (PWG), and in part by NIH grant No. DK53452 and the Ohio Cancer Research Associates (ARB).

Author information

Authors and Affiliations

  1. Department of Cancer Endocrinology, BC Cancer Agency, Vancouver, BC, Canada

    PW Gout, CR Simms & N Bruchovsky

  2. College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA

    AR Buckley

Authors
  1. PW Gout
    View author publications

    Search author on:PubMed Google Scholar

  2. AR Buckley
    View author publications

    Search author on:PubMed Google Scholar

  3. CR Simms
    View author publications

    Search author on:PubMed Google Scholar

  4. N Bruchovsky
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gout, P., Buckley, A., Simms, C. et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drug. Leukemia 15, 1633–1640 (2001). https://doi.org/10.1038/sj.leu.2402238

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2402238

Keywords

This article is cited by

Search

Advanced search

Quick links